Kalshi seeks CFTC approval for risk-based margining on event contracts

Kalshi is seeking CFTC approval to introduce risk-based margining for selected event contracts, a move that would reduce collateral requirements for traders. The platform is currently fully collateralized. The filing targets institutional traders and would shift from a flat collateral model to one that varies by contract type and market conditions. Kalshi has also separately filed to list perpetual futures on US stocks and ETFs.

Why this matters?

Margin approval would let Kalshi compete directly with brokerage options accounts that already offer leveraged equity exposure. Robinhood already drives the largest prediction-market revenue stream of any retail brokerage, and its users expect margin as standard. Without it, Kalshi risks looking like a toy inside a real trading app.

The filing's scope matters for ForecastEx and Polymarket too: whichever platform first cracks margin rules for event contracts will set the collateral and eligibility template rivals must match. CFTC delay is the real threat here. Every month without approval lets offshore venues keep their leverage advantage intact.

The bigger picture

Kalshi's separate CFTC margin filing for event contracts and recent SEC-CFTC filings for single-stock perpetuals now give it two paths to leveraged equity exposure, joining the ~60 single-stock perpetual futures it filed days earlier as the platform races to define the regulated template before Coinbase or Kraken match it.

For more stories, check out PredictionNews.

Go to PredictionNews.com

CFTC scrutinizes $5 billion in near-identical Kalshi ether trades

Why this matters?

Kalshi's $5 billion in near-identical trades puts its volume data at the center of a credibility fight it cannot afford to lose. Traders use that data to size liquidity risk before committing capital; persistent authenticity questions push them toward competitors with cleaner numbers. The CFTC is already reviewing perpetual-futures filings with heightened surveillance standards, so unresolved allegations invite scrutiny that could delay product approvals.

Kalshi's flat denial offered no published methodology to close the gap. Competitors with sharper volume transparency can capture migrating flow during the peak NFL season. The platform's daily volume figure becomes a liability rather than a marketing asset if it cannot produce audited, single-event numbers faster than rivals can match its product suite. Whoever publishes verified volume first will set the transparency bar the rest must clear.

CFTC warns 'mention market' prediction contracts carry manipulation risk

Atlantic Council launches sports policy center with Kalshi backing

Why this matters?

Kalshi is building influence outside trading floors just as tribal opposition and Polymarket's LeBron James deal squeeze it on two fronts. The Atlantic Council partnership gives Kalshi a policy voice to shape how regulators and lawmakers think about sports event contracts before courtrooms do. That matters because the Tunica-Biloxi deal fractured tribal unity Kalshi faces in Ninth Circuit cases, and James now gives Polymarket the marketing edge Kalshi never held alone.

The Power of Sports Center lets Kalshi seed research and convenings that define sports contracts as economic infrastructure, not gambling. Polymarket has no comparable think tank conduit. The platform that wins the policy narrative will ease its own regulatory path while its rival spends on celebrity instead.

Bioethicist Kimmelman calls out ethical risks in Kalshi's drug markets

Why this matters?

Kalshi's drug markets expose a gap that CFTC-market oversight does not close. Kimmelman's critique centers on how financial incentives distort scientific judgment: traders with stakes in FDA outcomes may pressure researchers, amplify premature signals, or crowd into consensus positions that flatten genuine uncertainty. This pressure lands first on clinical investigators and biostatisticians, who face new audiences treating their interim data as tradable events.

Kalshi must now guard against becoming a venue that moves the science it prices, a reputational risk that ForecastEx and Polymarket sidestep by not listing pharmaceutical contracts. The platform's CFTC registration gives it credibility, but that same stamp makes Kalshi the natural scapegoat if a high-profile trial leak or trading surge precedes a bad regulatory surprise. Drugmakers watching the episode will weigh whether Kalshi markets help or hurt their approval narratives, and the first sponsor to publicly disavow prediction-market tracking of its pipeline will force rivals to take sides.

Ninth Circuit rules Kalshi sports event contracts constitute illegal gambling

Why this matters?

Creates judicial precedent that event contracts in sports partnerships may constitute illegal gambling under federal law, exposing prediction market platforms to similar challenges when they team with leagues or franchises.

The bigger picture

Second Ninth Circuit ruling this month to reject Kalshi's federal preemption theory for sports event contracts, after Nevada loss and California tribal lands decision, with Robinhood and Crypto.com also petitioning the Supreme Court for a uniform national rule.

The Resolution.

by Prediction News

Sent from a single address. We use your email only to deliver the brief. One-click unsubscribe; we never sell, share, or rent the list.

The Resolution archive →

PredictionNews.com →

848 N Rainbow Blvd, Suite #499, Las Vegas NV 89107